Cramer JA - Search Results

1

A systematic review of persistence and compliance with bisphosphonates for osteoporosis.

Cramer JA, Gold DT, Silverman SL, Lewiecki EM. Cramer JA, et al. Osteoporos Int. 2007 Aug;18(8):1023-31. doi: 10.1007/s00198-006-0322-8. Epub 2007 Feb 17. Osteoporos Int. 2007. PMID: 17308956 Review.

2

Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.

Cramer JA, Silverman S. Cramer JA, et al. Am J Med. 2006 Apr;119(4 Suppl 1):S12-7. doi: 10.1016/j.amjmed.2005.12.018. Am J Med. 2006. PMID: 16563936 Review.

3

Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis.

Cramer JA, Silverman SL, Gold DT. Cramer JA, et al. Curr Med Res Opin. 2007 Oct;23(10):2369-77. doi: 10.1185/030079907X226311. Curr Med Res Opin. 2007. PMID: 17711617

4

Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies.

Silverman SL, Gold DT, Cramer JA. Silverman SL, et al. Among authors: cramer ja. South Med J. 2007 Dec;100(12):1214-8. doi: 10.1097/SMJ.0b013e31815a9685. South Med J. 2007. PMID: 18090964 Review.

5

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.

Cramer JA, Amonkar MM, Hebborn A, Altman R. Cramer JA, et al. Curr Med Res Opin. 2005 Sep;21(9):1453-60. doi: 10.1185/030079905X61875. Curr Med Res Opin. 2005. PMID: 16197664

6

Non-compliance: the Achilles' heel of anti-fracture efficacy.

Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jönsson B, Pols H, Cramer JA. Seeman E, et al. Among authors: cramer ja. Osteoporos Int. 2007 Jun;18(6):711-9. doi: 10.1007/s00198-006-0294-8. Epub 2007 Jan 24. Osteoporos Int. 2007. PMID: 17245547 Review.

7

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.

Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. Cramer JA, et al. Int J Clin Pract. 2008 Jan;62(1):76-87. doi: 10.1111/j.1742-1241.2007.01630.x. Epub 2007 Nov 5. Int J Clin Pract. 2008. PMID: 17983433 Free PMC article. Review.

8

The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.

Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. Cramer JA, et al. Clin Ther. 2006 Oct;28(10):1686-94. doi: 10.1016/j.clinthera.2006.10.013. Clin Ther. 2006. PMID: 17157124

9

Medication compliance and persistence: terminology and definitions.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Cramer JA, et al. Value Health. 2008 Jan-Feb;11(1):44-7. doi: 10.1111/j.1524-4733.2007.00213.x. Value Health. 2008. PMID: 18237359 Free article. Review.

10

Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence.

Cramer JA. Cramer JA. Am J Manag Care. 1998 Nov;4(11):1563-8. Am J Manag Care. 1998. PMID: 10338902 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page